Neoadjuvant Therapy and Axillary Lymph Node Status in HER2-Positive Breast Cancer

References

• Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. doi:10.1016/j.annonc.2021.06.023.
   PubMed Web of Science ®Google Scholar
• Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12–S16. doi:10.1016/j.breast.2022.01.006.
   PubMedGoogle Scholar
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8.
   PubMed Web of Science ®Google Scholar
• Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2(6):751–760. doi:10.1001/jamaoncol.2015.6113.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. doi:10.1016/S1470-2045(16)00163-7.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131. doi:10.1056/NEJMoa1703643.
   PubMed Web of Science ®Google Scholar
• Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the aphinity trial: 6 years’ follow-up. J Clin Oncol. 2021;39(13):1448–1457. doi:10.1200/JCO.20.01204.
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410. doi:10.1111/j.1365-2559.1991.tb00229.x.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. doi:10.1200/JCO.2009.25.6529.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. doi:10.5858/arpa.2013-0953-SA.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–750. doi:10.1093/jnci/djp082.
   PubMed Web of Science ®Google Scholar
• Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8):1168–1176. doi:10.1200/JCO.2008.18.1024.
   PubMed Web of Science ®Google Scholar
• Cha C, Ahn SG, Kim D, Lee J, Park S, Bae SJ, et al. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Int J Cancer. 2021;149(8):1585–1592. doi:10.1002/ijc.33726.
   PubMed Web of Science ®Google Scholar
• Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482–493. doi:10.1245/s10434-017-6263-y.
   PubMed Web of Science ®Google Scholar
• Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156(6):e210891. doi:10.1001/jamasurg.2021.0891.
   PubMed Web of Science ®Google Scholar
• Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). Ann Surg. 2017;266(4):667–676. doi:10.1097/SLA.0000000000002373.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2019;176(3):591–596. doi:10.1007/s10549-019-05214-y.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gonzalez S, Falo C, Pla MJ, Verdaguer P, Nunez D, Guma A, et al. Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy. Breast J. 2020;26(5):888–896. doi:10.1111/tbj.13763.
   PubMed Web of Science ®Google Scholar
• Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152(7):665–670. doi:10.1001/jamasurg.2017.0562.
   PubMed Web of Science ®Google Scholar
• Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): A review of 20,000 breast cancer patients in the national cancer data base (NCDB). Ann Surg. 2018;268(4):591–601. doi:10.1097/SLA.0000000000002953.
   PubMed Web of Science ®Google Scholar